Inactive Instrument

APTINYX

Equities

APTX

US03836N1037

Aptinyx Inc. Announces Principal Financial Officer Changes

July 03, 2023 at 01:31 pm EDT

On June 30, 2023, Andrew Kidd, stepped down from his position as principal financial officer of Aptinyx Inc. On June 30, 2023, following Mr. Kiddâ€™s resignation, Craig Jalbert was appointed principal financial officer of the Company.

Latest news about APTINYX

Aptinyx Inc. Approves Liquidating Cash Distribution, Payable on or About December 29, 2023	Dec. 18	CI
North American Morning Briefing : Concerns About -2-	23-09-07	DJ
North American Morning Briefing : PCE Inflation -2-	23-08-31	DJ
North American Morning Briefing : Nasdaq Futures -2-	23-08-24	DJ
North American Morning Briefing : Treasury Yields Keep Pushing Higher	23-08-17	DJ
Aptinyx Inc. Announces Chief Executive Officer Changes	23-07-03	CI
Aptinyx Inc. Announces Management Changes	23-07-03	CI
Aptinyx Inc. Announces Principal Financial Officer Changes	23-07-03	CI
Aptinyx Inc. is Heading Towards Bankruptcy	23-05-23	CI
Aptinyx Inc.(OTCPK:APTX) dropped from S&P TMI Index	23-05-23	CI
Aptinyx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-18	CI
North American Morning Briefing : Stocks to Extend -3-	23-05-18	DJ
Aptinyx Inc.(OTCPK:APTX) dropped from NASDAQ Composite Index	23-05-18	CI
Aptinyx Inc. Announces Executive Changes	23-05-05	CI
Aptinyx Inc. Announces Departure of Ashish Khanna as Chief Financial Officer	23-05-05	CI
Aptinyx Inc. Announces Departure of Andy Kidd, Chief Executive Officer	23-05-05	CI
Aptinyx Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Aptinyx Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-30	CI
Aptinyx Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
North American Morning Briefing : Stock Futures -3-	23-03-08	DJ
HC Wainwright Downgrades Aptinyx to Neutral From Buy	23-03-07	MT
North American Morning Briefing : Rising Yields -3-	23-03-02	DJ
SVB Securities Downgrades Aptinyx to Market Perform From Outperform, Price Target is $0.50	23-03-01	MT
Aptinyx Inc. to Reduce its Workforce by Approximately 60%	23-03-01	CI
Top Premarket Decliners	23-02-28	MT

Chart APTINYX

Duration

Period

More charts

Company Profile

Aptinyx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The Company focuses on targeting and modulating N-methyl-D-aspartate receptors, (NMDArs), which are vital to the normal and effective function of the brain and nervous system. The Company's NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder (OUD), and in preclinical development for the treatment of alcohol use disorder. NYX-783 modulates NMDA receptors to increase glutamatergic activity in key regions and may act to enhance extinction learning and alleviate the emotional symptoms of opioid withdrawal. The Company's NMDAr modulator discovery platform builds on NMDAr biology. The platform has the potential to develop into a broad pipeline and product portfolio across an array of disorders of the brain and nervous system.

Sector

More about the company